Selected EMA news, April 2026

New information on approved medicines 

• Besponsa (inotuzumab ozogamicin) – new indication
  Treatment of leukemia (a type of blood cancer)

• Feraccru (ferric maltol) – change of indication
  Treatment of iron deficiency

• Hympavzi (marstacimab) – change of indication
  Prevention of bleeding episodes with blood clotting disorders, Hemophilia A and Hemophilia B

Other EMA news and events 

• A workshop on immune thrombocytopenia will be held on June 30, 2026 between 14:00-18:00. The workshop will discuss multi-stakeholder perspectives on the challenges in drug development, regulation and clinical practice in this disease. Registration is open until 22 June. 

• EMA has published a new call for expressions of interest for scientific and regulatory experts, including experts in hematology. Successful applicants will be selected based on the published criteria and included in a dedicated pool of external experts. 

• EMA is launching a new pilot program in Q2 2026 to support breakthrough medical devices and in vitro diagnostics. The initiative aims to speed up patient access to highly innovative technologies by offering enhanced regulatory support and scientific advice, while maintaining high EU safety and performance standards.